Vascular Protection by Ketanserin, a 5-HT₂ Serotonergic Receptor Antagonist?

References

• Ross R, Bowen-Pope D F, Raines E W. Platelets, macrophages, endothelium and growth factors. Their effects upon cells and their possible roles in atherogenesis. Am NY Acad Sci 1985; 454: 254–269
   PubMed Web of Science ®Google Scholar
• Bertele B, Salzman E W. Anti-thrombotic therapy in coronary artery disease. Arteriosclerosis 1985; 5: 119–134
   PubMedGoogle Scholar
• Harker L A, Ritchie J L. The role of platelets in acute vascular events. Circulation 1980; 62: V13–V18, Suppl V
   PubMed Web of Science ®Google Scholar
• Woolf N. Thrombosis and Atherosclerosis. Haemostasis and thrombosis, A L Bloom, D P Thomas. Churchill Livingstone, Edinburgh 1981; 527–553
   Google Scholar
• Vermylen J, Verstraete M, Fuster V. Role of platelet activation and fibrin formation in thrombogenesis. J Am Coll Cardiol 1986; 8: 2B–9B
   PubMed Web of Science ®Google Scholar
• Nemecek G M, Coughlin S R, Handley D A, Moskowitz M A. Stimulation of aortic smooth muscle cell mitogenesis by serotonin. Proc Natl Acad Sci USA 1986; 83: 674–678
   PubMed Web of Science ®Google Scholar
• Vanhoutte P M, Houston D S. Platelets, endothelium and vasospasm. Circulation 1985; 72: 728–734
   PubMed Web of Science ®Google Scholar
• Bevers E M, Rosing J, Zwaal R F N. Platelets and coagulation. Platelets in biology and pathology III, D E Mac Intyre, J L Gordon. Elsevier, Amsterdam 1987; 127–160
   Google Scholar
• Clerck FD, de Chaffoy Courcelles D. Amplification mechanisms in platelet activation. Blood cells and arteries in hypertension and atherosclerosis, P Meyer, P Marche. Raven Press, New York 1989; 105–140
   Google Scholar
• Fuster V, Badimon L, Badimon J, Adams P C, Turitto V, Chesebro J M. Drugs interfering with platelet functions: mechanisms and clinical relevance. Thrombosis and haemostasis, M Verstraete, J Vermylen, R Lijnen, J Arnout. Leuven University Press, Leuven 1987; 349–418
   Google Scholar
• Poller L. Oral anticoagulant therapy. Haemostasis and thrombosis, A L Bloom, D P Thomas. Churchill Livingstone, Edinburgh 1981; 725–736
   Google Scholar
• Kelton J G, Hirsh J. Antiplatelet agents: rationale and results. Haemostasis and thrombosis, A L Bloom, D P Thomas. Churchill Livingstone, Edinburgh 1981; 737–760
   Google Scholar
• Kakkar V V, Sasahara A A, Thomas D P. Treatment of venous thromboembolism. Haemostasis and thrombosis, A L Bloom, D P Thomas. Churchill Livingstone, Edinburgh 1981; 684–692
   Google Scholar
• Van Nueten J M, Janssen P A J, Symoens J, . Ketanserin. New cardiovascular drugs, A Scriabine, F De Clerck, et al. Raven Press, New York 1987; 1–56
   Google Scholar
• Robertson J I S, Andrews T M. Free serotonin in human plasma: quantitative and qualitative estimation. Lancet 1961; 1: 578–580
   PubMed Web of Science ®Google Scholar
• Ashton J H, Benedict C R, Fitzgerald C, et al. Serotonin as a mediator of cyclic flow variations in stenosed canine coronary arteries. Circulation 1986; 73: 572–578
   PubMed Web of Science ®Google Scholar
• Rooman R P, Moeremans M, Dewever B, . Ketanserin in wound healing and fibrosis: Investigations into its mechanism of action. Serotonin. From cell biology to pharmacology and therapeutics, R Paoletti, P M Vanhoutte, N Brunello, F M Maggi, et al. Kluwer Academic Publishers, Dordrecht 1990; 451–456
   Google Scholar
• Boucek R J, Alvarez T R. 5-Hydroxytryptamine: a cytospecific growth stimulator of cultured fibroblasts. Science 1970; 167: 898–899
   PubMed Web of Science ®Google Scholar
• Boucek R J, Alvarez T R. Increase in survival of subcultured fibroblasts mediated by serotonin. Nature 1971; 229: 61–62
   Google Scholar
• Bazin S, Pelletier M, Delaunay A. The influence of chemical mediators of acute inflammation on the cells of a subacute inflammation. Agents Actions 1973; 3: 317–322
   Google Scholar
• Mann P R. Effects of various substances on DNA synthesis in guinea-pig skin in vitro. Nature 1967; 216: 715–716
   Google Scholar
• Aalto M, Kulonen E. Effects of serotonin, indomethacin and other antirheumatic drugs on the synthesis of collagen and other proteins in granulation tissue slices. Biochem Pharmacol 1972; 21: 2835–2840
   PubMed Web of Science ®Google Scholar
• Boucek R J, Speropoulos A J, Noble N L. Serotonin and ribonucleic acid and collagen metabolism of fibroblasts in vitro. Proc Soc Exp Biol Med 1972; 140: 599–603
   PubMed Web of Science ®Google Scholar
• Rossi P, Zamboni L. Pulmonary atherosclerosis due to serotonin. Nature 1958; 181: 1216–1217
   Google Scholar
• Ahmed F S, Harrison C V. Morphological effects of serotonin on pulmonary arteries: an experimental study in rabbits. J Pathol Bact 1964; 87: 325
   Google Scholar
• Chesebro J H, Lam J Y T, Fuster V. The pathogenesis and prevention of aortocoronary vein bypass graft occlusion and restenosis after arterial angioplasty: role of vascular injury and platelet thrombus deposition. J Am Coll Cardiol 1986; 8: 57B–66B
   Google Scholar
• Heistad D D, Armstrong M L, Marcus M L, Peigors D J, Mark A L. Augmented responses to vasoconstriction stimuli in hypercholesterolenemic and atherosclerotic monkeys. Circ Res 1984; 54: 711–718
   PubMed Web of Science ®Google Scholar
• Verbeuren T J. 5HT, platelets and experimental atherosclerosis. Serotonin. From cell biology to pharmacology and therapeutics, R Paoletti, P M Vanhoutee, N Brunello, F M Maggi. Kluwer Academic Publishers, Dordrecht 1990; 131–136
   Google Scholar
• Heistad D D, Lopez J A G, Mayhan W G. Responses to serotonin in atherosclerotic and hypertensive blood vessels. Serotonin. From cell biology to pharmacology and therapeutics, R Paoletti, P M Vanhoutte, N Brunello, F M Maggi. Kluwer Academic Publishers, Dordrecht 1990; 137–140
   Google Scholar
• Shimokawa H, Aarho L L, Vanhoutte P M. Porcine coronary arteries with regenerated endothelium have a reduced endothelium-dependent responsiveness to aggregating platelets and serotonin. Circ Res 1987; 61: 256–270
   PubMed Web of Science ®Google Scholar
• Verheyen A, Lauwers F, Vlaminckx E, Wouters L, De Clerck F. Effects of vasoactive agonists on peripheral collateral arteries in in vitro perfused rat hind quarters. Supersensitivity to serotonin. Int J Microcirc 1988; 7: S132
   Google Scholar
• De Clerck F, Loots W, Jageneau A, Nevelsteen A. Correction by ketanserin of the platelet-mediated inhibition of peripheral collateral circulation in the cat: measurement of blood flow with radioactive microspheres. Drug Dev Res 1986; 8: 149–158
   Google Scholar
• Hollenberg N. Serotonin, atherosclerosis and collateral vessel spasms. Am. J Hypertens 1988; 1: 312S–316S
   Google Scholar
• Vanhoutte P M, Van Nueten J M, Janssen W J. Vascular serotonin receptors and cardiovascular disease. Serotonin. From cell biology to pharmacology and therapeutics, R Paoletti, P M Vanhoutte, N Brunello, F M Maggi. Kluwer Academic Publishers, Dordrecht 1990; 81–96
   Google Scholar
• Mustard J F, Packard M A, Kinlough-Rathbone R L. Mechanisms in thrombosis. Haemostasis and thrombosis, A L Bloom, D P Thomas. Churchill Livingstone, Edinburgh 1981; 503–526
   Google Scholar
• Osim E E, Wyllie J H. Evidence for loss of 5-hydroxytryptamine from circulating platelets. J Physiol 1982; 326: 25P–26P
   Google Scholar
• Bush L, Campbell W B, Kenn K, Tilton G P, Apprill P, Ashton J, Schmitz J, Buja L M, Willerson J T. The effects of alpha2-adrenergic and serotonergic receptor antagonists on cyclic blood flow alterations in stenosed canine coronary arteries. Circ Res 1984; 55: 642–652
   PubMed Web of Science ®Google Scholar
• Golino P, Buja L M, Ashton J H, Kulkanni P, Taylor A, Willerson J T. Effect of thromboxane and serotonin receptor antagonists on intracoronary platelet deposition in dogs with experimentally stenosed coronary arteries. Circulation 1988; 78: 701–711
   Google Scholar
• De Clerck F, Loots W, Somers Y, et al. 5-Hydroxytryptamine and arachidonic acid metabolites modulate extensive platelet activation induced by collagen in cats in vivo. Br J Pharmacol 1990; 99: 631–636
   Google Scholar
• Golino P, Ashton J M, Glas-Greenwalt P, McNatt J, Buja L M, Willerson J T. Mediation of reocclusion by thromboxane-A2 and serotonin after thrombolysis with tissue-type plasminogen activator in a canine preparation of coronary thrombosis. Circulation 1988; 77: 678–684
   PubMedGoogle Scholar
• Chesebro J H, Lam J Y T, Fuster V. The pathogenesis and prevention of aortocoronary vein bypass graft occlusion and restenosis after arterial angioplasty: role of vascular injury and platelet thrombus deposition. J Am Coll Cardiol 1986; 8: 57B–66B
   Google Scholar
• Klein W, Brandt D, Eber B, Dusleag J. Prävention der frühen Restenosierung nach Perkutaner transluminaler Koronarangioplastie mit Serotonin-Antagonisten. Cor Vasa 1988; 2: 234–237
   Google Scholar
• Noble M I M, Drake-Holland A. Prevention of atherosclerotic complications with ketanserin. Br Med J 1989; 298: 752
   Google Scholar
• PACK Trial Group. Prevention of atherosclerotic complications: Controlled trial of ketanserin. Br Med J 1989; 298: 424–430
   PubMed Web of Science ®Google Scholar
• PACK Trial Group. Randomized placebo-controlled, double-blind trial of ketanserin in claudicants: changes in claudication distance and ankle systolic pressure. Circulation 1989; 80: 1544–1548
   Google Scholar
• Chalmers T C, Murray G D. Retrospective analyses for hypothesis generation: a commentary on the PACK trial (Prevention of Atherosclerotic Complications with Ketanserin). Clin Exp Hypertens 1989; A11: 1117–1136
   Google Scholar
• Doyle A E. Serotonin antagonists and vascular protection. Cardiovasc Drugs Ther 1990; 4: 11–16, Suppl 1
   Google Scholar